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Abstract
Noxa is a Bcl-2-homology domain (BH3)-only protein reported to be a proapoptotic member of the Bcl-2 family. Estrogen
has been well documented to stimulate cell growth and inhibit apoptosis in estrogen receptor (ER)-positive breast cancer
cells. Intriguingly, recent reports have shown that 17b-estradiol (E2) induces Noxa expression, although the mechanisms
underlying E2-mediated induction of Noxa and its functional significance are unknown. Using MCF7 human breast cancer
cells as an experimental model, we show that Noxa is upregulated by E2 via p53-independent processes that involve c-Myc
and ERa. Experiments using small interfering ribonucleic acids (siRNA) to specifically knock down p53, c-Myc, and ERa
demonstrated that c-Myc and ERa, but not p53, are involved in the transcriptional upregulation of Noxa following E2
treatment. Furthermore, while E2 promoted the recruitment of c-Myc and ERa to the NOXA promoter in chromatin
immunoprecipitation (ChIP) assays, E2 did not induce p53 recruitment. Interestingly, E2-mediated upregulation of Noxa was
not associated with apoptosis. However, siRNA-mediated knockdown of Noxa resulted in cell cycle arrest in G0/G1-phase
and significantly delayed the G1-to-S-phase transition following E2 treatment, indicating that Noxa expression is required for
cell cycle progression in ER-positive breast cancer cells.
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Introduction
Noxa/Phorbol 12-myristate 13-acetate (PMA)-Induced Protein
1 (PMAIP1)/Adult T-cell Leukemia-derived PMA-responsive
(APR) is a proapoptotic Bcl-2-homology domain 3 (BH3)-only
member of the Bcl-2 family of proteins [1]. The Bcl-2 family of
proteins is subdivided into three different classes, according to
conservation of the Bcl-2 homology (BH) domains, BH1-4 [2–6].
The first class consists of the multi-domain prosurvival proteins,
which include Bcl-2, Bcl-xL, Mcl-1, Bcl-w/BCL2L2, Bfl-1/A1,
and Bcl-B/Bcl2L10; the second class consists of the multi-domain
proapoptotic proteins, which include Bax, Bak, and Bok/Mtd; the
third class consists of the BH3-only proapoptotic proteins, which
include Noxa, Puma, Bid, Bad, Bim, Bik, Bmf, and Hrk. [2–7].
Various combinations of these three classes of Bcl-2 proteins come
together to form heterodimeric complexes at the mitochondria,
resulting in the induction or suppression of apoptosis. While the
BH3-only proteins Puma, Bid, and Bim can induce apoptosis by
directly interacting with and activating the multidomain proa-
poptotic members (such as Bax and Bak), Noxa induces apoptosis
by suppressing prosurvival Mcl-1 [8–11]. Under normal cellular
conditions, proapoptotic Bak is maintained as a heterodimer with
prosurvival Mcl-1; however, in response to various cellular stresses,
Noxa becomes upregulated and competes with Bak for binding to
Mcl-1, thereby releasing Bak from prosurvival Mcl-1 and initiating
Bak-mediated apoptosis [8–10,12,13].
Recent studies have shown that Noxa plays important roles in
many physiological processes other than apoptosis. In human
ovarian surface epithelial cells, Noxa is required for Ras-induced
autophagy [14]. In Bcl-2 overexpressing MCF7 cells, cisplatin-
induced Noxa expression is required for lipid peroxidation [15].
Furthermore, some studies suggest that Noxa may play a pro-
survival role under certain contexts. In acute lymphoblastic
leukemia cells, Noxa is repressed during glucocorticoid-induced
apoptosis [16], and Noxa also promotes cell growth by stimulating
glucose consumption via the pentose phosphate pathway [17,18].
These data highlight the multiple roles of Noxa as a context-
dependent regulator of many different physiological processes,
including, but not limited to, apoptosis.
Although Noxa is traditionally known to be a transcriptional
target gene of tumor suppressor p53 due to its well-defined role in
p53-mediated apoptosis [1,2,5,19–21], many p53-independent
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e29466mechanisms of Noxa upregulation have been identified, also. For
example, the transcription factors c-Myc [22], Hypoxia-Inducible
Factor (HIF)-1a [23], cAMP Response Element Binding Protein
(CREB) [24] and E2F Transcription Factor 1 (E2F1) [25] have
been described to mediate p53-independent transcription of Noxa.
Furthermore, recent studies have shown that 17b-estradiol (E2)
induces Noxa expression in breast cancer cells [26,27], although
the mechanisms underlying E2-mediated induction of Noxa have
not been reported. Notably, E2 is well-documented to stimulate
cell growth and promote cell cycle progression in estrogen receptor
(ER)-positive breast tumors [28–30]. As the majority of breast
cancers are initially hormone-dependent [31,32], E2-mediated
upregulation of Noxa expression could be of particular relevance
to breast tumor biology. However, the functional significance of
E2-mediated upregulation of Noxa in breast cancer cells has not
been thoroughly studied, and the relationship between E2-
dependent induction of Noxa and E2-dependent stimulation of
cell growth remains to be elucidated.
Here we report that E2 induces Noxa expression via p53-
independent pathways that are mediated by c-Myc, ERa, and
E2F1/RB. For the first time, we show that knocking down Noxa
inhibits E2-induced cell cycle progression in breast cancer cells,
suggesting a novel role for Noxa as a cell cycle regulator in ER-
positive breast tumors.
Results
c-Myc mediates E2-induced Noxa transcription in human
breast cancer cells
It has been reported that Noxa is upregulated in response to E2
treatment in breast cancer cells [26,27], and Noxa expression is
co-clustered with ERa expression in breast tumors [27].
Consistent with these previous reports, we found that Noxa
protein and mRNA were upregulated in response to E2 treatment
in estrogen-responsive MCF7 human breast cancer cells (Fig. 1A &
1B). It has been reported that NOXA is a transcriptional target
gene of c-Myc [22] and that MYC is a transcriptional target gene
of E2 [33]. Therefore, we tested if E2-dependent induction of
Noxa is mediated by c-Myc. E2 treatment induced c-Myc
expression (Fig. 1C) and increased the amount of c-Myc protein
that was bound to the NOXA promoter (Fig. 1D), as assayed by
chromatin immunoprecipitation (ChIP) assays. Transient trans-
fection of c-Myc small interfering RNA (siRNA) substantially
knocked down c-Myc protein expression (Fig. 1E) and partially
blocked E2-dependent induction of Noxa (Fig. 1F). As a positive
control, knocking down c-Myc also blocked E2-dependent
induction of nucleolin (NCL) (Fig. 1G), which was previously
reported to be an E2-responsive transcriptional target gene of c-
Myc [34]. These data collectively indicate that E2 induces Noxa
expression via a mechanism that is partially dependent upon c-
Myc; however, additional mechanisms likely exist, as loss of c-Myc
did not completely abolish E2’s ability to induce Noxa expression
(Fig. 1F).
E2-induced Noxa transcription is ERa-dependent and
p53-independent
Since the primary mechanism of action of E2 is elicited through
ERa, we tested if ERa contributed to E2-induced Noxa
expression, in addition to c-Myc. Indeed, analysis of Noxa mRNA
levels in MCF7 cells showed that the antiestrogens tamoxifen and
ICI 182780 (fulvestrant) antagonized E2-induced upregulation of
Noxa (Fig. 2A), suggesting the involvement of ERa. Furthermore,
when ERa was knocked down (Fig. 2B), E2-induced Noxa
expression was drastically reduced (Fig. 2C), demonstrating that
E2-induced Noxa expression is ERa-dependent. As a positive
control, E2-dependent induction of pS2 (TFF1), a prototypic
transcriptional target gene of ERa, was also reduced when ERa
was knocked down (Fig. 2D). Notably, although Noxa expression is
highly regulated by p53, E2-dependent induction of Noxa
expression appears to be a p53-independent process because
transient knock down of p53 (Fig. 2B) did not affect the ability of
E2 to induce Noxa expression (Fig. 2C). Consistent with this result,
E2 treatment did not result in the recruitment of p53 to the NOXA
promoter, as compared to treatment with the DNA damaging
agents doxorubicin and adozelesin (Fig. 2E), which were used as
positive controls. These data indicate that under conditions that do
not cause genomic damage, ERa regulates Noxa expression via a
p53-independent process.
E2F1 mediates ERa-binding to the NOXA promoter in the
presence of E2
After determining that ERa is a mediator of E2-dependent
induction of Noxa, we next tested if NOXA is a direct
transcriptional target of ERa. We identified a putative estrogen
response element (ERE) within the NOXA promoter at 23.7 Kb
(Fig. 3A) by using the ‘Dragon ERE Finder’ program [35].
However, instead of binding to this putative ERE site, we found
that ERa was recruited to the proximal region of the NOXA
promoter in ChIP assays (Fig. 3B, compare lanes 3 & 9). Since
no ERE was identified in the proximal region of the NOXA
promoter, we hypothesized that ERa was accessing the DNA by
tethering onto other proteins. It has been reported that the
murine NOXA gene is a transcriptional target of E2F1 [25], and
a potential E2F binding site has been identified within the
human NOXA promoter [22], near the site at which we observed
ERa binding (Fig. 3A). Therefore, we tested if ERa was able to
bind to E2F1 protein directly, which would suggest that ERa
might access the NOXA promoter by tethering to DNA-bound
E2F1. The results of co-immunoprecipitation experiments
showed that ERa and E2F1 coexisted in a single protein
complex in MCF7 cells (Fig. 3C). Consistent with these data,
site-specific ChIP assays showed that both E2F1 and its partner,
the retinoblastoma tumor suppressor protein (RB), were present
on the region of the NOXA promoter to which ERa binds
(Fig. 3D, upper panel). E2 treatment augmented ERa binding
but decreased RB binding to the NOXA promoter (Fig. 3D,
u p p e rp a n e l ,c o m p a r el a n e s3&8a n d5&1 0 ) ;h o w e v e r ,t h e
binding of RB to the NOXA promoter was not affected by E2
when ERa was knocked down (Fig. 3D, compare lanes 5 & 10 of
upper panel to lanes 5 & 10 of lower panel). These data indicate
that in the absence of E2, E2F1 recruits RB to the NOXA
promoter, whereas in the presence of E2, E2F1 recruits ERa on
the NOXA promoter. This inverse correlation between ERa and
RB binding to the NOXA p r o m o t e ri nt h ep r e s e n c eo fE 2
suggests that ERa and RB may be recruited to the NOXA
promoter via E2F1 in mutually exclusive manners, although this
remains to be formally tested. In support of the hypothesis that
E2F1 is required for E2 to be able to increase the amount of
ERa that is recruited to the NOXA promoter, we found that
when E2F1 was knocked down (Fig. 3E, left panel), E2 was
unable to increase ERa recruitment (compare lanes 3 & 6 of
Fig. 3E, right panel, to lanes 3 & 8 of Fig. 3D, upper panel). As a
consequence, the ability of E2 to induce Noxa expression was
reduced when E2F1 was knocked down (Fig. 3F). Together,
these data suggest that ERa is recruited to the NOXA promoter
by E2F1 and that E2F1 is required for ERa to mediate
upregulation of Noxa in response to E2 treatment.
Estrogen Upregulates Noxa in Breast Cancer Cells
PLoS ONE | www.plosone.org 2 December 2011 | Volume 6 | Issue 12 | e29466Noxa knock-down arrests cells in G1/G0-phase and delays
E2-induced S-phase entry
It has been well-documented that E2 stimulates the growth of
ER-positive breast cancer cells by promoting the G1-to-S-phase
transition and that Noxa plays a prominent role in apoptosis.
Therefore, to analyze the physiological response of E2-mediated
inductionofNoxa inER-positivebreast cancercells,weinvestigated
how loss of Noxa affected cell viability, cell cycle progression, and
apoptosis under normal physiological conditions, in the absence of
cellular stress. We used three different siRNAs that specifically
target Noxa to knock down Noxa mRNA and protein expression in
MCF7 cells (Fig. 4A & B). As compared to transfection with non-
silencing control (NS) siRNA, transfection with Noxa siRNA caused
a more than 50% reduction in cell viability when viability was
assayed 48 hr post-transfection (Fig. 4C). Therefore, we did
additional experiments to test if the loss of cell viability that we
observed when Noxa was knocked down was due to a reduction in
the rate of cell cycle progression or an increase in the rate of
apoptosis. Interestingly, the results of flow cytometric analysis of
propidium iodide (PI)-stained cells showed that knocking down
Noxa increases the length of the G1/G0-phase (Fig. 4D), supporting
a role for Noxa as a regulator of the G1-to-S phase transition. This
raises the possibility that E2-dependent induction of Noxa may be
required for E2 to stimulate cell cycle progression. Indeed, E2
treatment induced S-phase entry in MCF7 cells; however, E2-
mediated induction of S-phase entry was blocked when Noxa was
knocked down (Fig. 4E). Flow-cytometric analysis of the S-phase
population using Bromodeoxyuridine (BrdU) incorporation assays
showed similar results (data not shown). Notably, although Noxa is
typically a pro-apoptotic protein, we found that in the absence of
Figure 1. c-Myc mediates E2-induced Noxa transcription in human breast cancer cells. (A–C) MCF7 cells were treated with vehicle (veh) or
E2 (10 nM) for 16 hr and then harvested for analysis of Noxa protein expression by western blotting (A), Noxa mRNA expression by qPCR (B), and c-
Myc protein expression by western blotting (C). (D) MCF7 cells were treated with vehicle (veh) or E2 for 4 hr, and ChIP assays using anti-c-Myc
antibody or normal mouse IgG (M IgG, antibody control) were performed to analyze the effect of E2 on the recruitment of c-Myc to the NOXA
promoter. Immunoprecipitated ChIP DNA was analyzed by PCR using site-specific primers that amplify a region of the NOXA promoter that contains a
c-Myc binding site at +85 bp. (E) MCF7 cells were transfected with non-silencing control (NS) or c-Myc siRNA for 48 hr and then harvested for analysis
of c-Myc protein levels by western blotting. (F, G) MCF7 cells were transfected with non-silencing control (NS) or c-Myc siRNA for 24 hr, followed by
treatment with vehicle (veh) or E2 (10 nM) for 8 hr, and the relative mRNA expression levels of Noxa (F) and Ncl (G) were analyzed by qPCR. Graphical
data points in B, F, and G are means 6 S.D. of three independent experiments (** P,0.01, *** P,0.001).
doi:10.1371/journal.pone.0029466.g001
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with cell cycle progression (Fig. 4D & E), but not with apoptosis
(Fig. 4F), as assayed by Poly-ADP-Ribose Polymerase (PARP)
cleavage using doxorubicin treatment as a positive control. E2
treatment induced Noxa protein expression at 16 hr post-treatment
(Fig. 1A) but did not induce PARP cleavage at the same time point
(Fig. 4F), or even at later time points (Fig. 4F). Overall, these data
suggest that E2-mediated upregulation of Noxa is not sufficient to
induce apoptosis under normal, unstressed conditions, but that
upregulation of Noxa by E2 is a novel requirement for cell cycle
progression in ER-positive breast cancer cells.
Discussion
Estrogen (E2), as a mitogen, has been well documented to
stimulate cell growth and inhibit apoptosis in ER-positive breast
cancer cells [36]. Intriguingly, the present study and other recent
reports [26,27] have demonstrated that E2 induces Noxa
expression. While Noxa is well-known for its role as a proapoptotic
member of the Bcl-2 family, it has become increasingly evident
that Noxa plays many roles in other cellular processes, as well.
Therefore, we sought to investigate the mechanisms underlying
E2-induced Noxa expression and its physiological relevance to
ER-positive breast cancer.
First, we used siRNA-mediated protein knockdown approaches
to demonstrate that, in the absence of genomic-damaging agents
and cellular-stressing agents, E2 induces Noxa expression via p53-
independent mechanisms that involve ERa. This observation is
strengthened by the fact that while p53 was bound to the NOXA
promoter in response to treatment with DNA-damaging agents,
p53 failed to bind to the NOXA promoter in untreated cells and
E2-treated cells. However, E2 increased the ability of ERa to bind
to the NOXA promoter. This is consistent with E2 being able to
induce Noxa expression in breast cancer cells, which we report in
the present study and which has also been described by another
group of investigators [27]. Of note, Noxa expression was found to
be co-clustered with ERa expression in breast tumor biopsy
specimens [27], suggesting that ERa-dependent upregulation of
Noxa is of direct relevance to breast cancer biology. Thus, our
studies demonstrate that proproliferative ERa and proapoptotic
p53 differentially regulate the function of Noxa in unstressed
versus stressed contexts, respectively. Importantly, our data and
that of others suggest that Noxa appears to be playing a
proproliferative role in a p53-independent manner under certain
contexts, while under other contexts, Noxa has a p53-dependent
proapoptotic role. Future studies should clarify the mechanisms
that regulate the balance between these two opposing functions of
Noxa.
Previous reports have demonstrated that E2 induces the
expression of Noxa and c-Myc, and that c-Myc regulates Noxa
expression [22]; however, detailed mechanisms linking all of these
processes together remained to be identified. The data shown in
Figure 2. E2-induced Noxa transcription is ERa-dependent and p53-independent. (A) MCF7 cells were treated with vehicle (veh), 10 nM E2
alone, 10 nM E2 in combination with 1 mM tamoxifen (Tam), or 10 nM E2 in combination with 1 mM ICI 182780 (ICI) for various times. Four, 8, 16 and
24 hr after treatment, cells were harvested, and Noxa mRNA expression levels were analyzed by qPCR. (B, C, & D) MCF7 cells were transfected with
non-silencing control (NS), ERa, or p53 siRNA for 24 hr, followed by treatment with vehicle (veh) or E2 (10 nM) for 8 hr, and then harvested for
analyses of ERa, p53, and b-actin (internal control) protein expression by western blotting (B), Noxa mRNA expression by qPCR (C), and pS2 mRNA
expression by qPCR (D). (E) MCF7 cells were treated with vehicle (veh), E2 (10 nM), doxorubicin (DOX; 1.70 mM), adozelesin (ADO; 4 nM), or left
without treatment (NT) for 16 hr. Occupancy of p53 on the proximal region of the NOXA promoter was determined by ChIP assays, using anti-p53
antibody or normal mouse IgG (M IgG; control antibody) for immunoprecipitation. Graphical data points in A, C, and D are means 6 S.D. of three
independent experiments (*** P,0.001).
doi:10.1371/journal.pone.0029466.g002
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we provide evidence that E2 induces c-Myc expression which, in
turn, increases Noxa expression. Furthermore, we have discovered
novel crosstalk between ERa and E2F1/RB signaling pathways in
the upregulation of Noxa. It has been shown previously that E2
treatment increases E2F1 protein levels, thereby affecting E2F1-
mediated transcription in MCF7 cells [37]. We report that E2F1
mediates an E2-dependent increase in the amount of ERa that is
bound to the NOXA promoter, resulting in the upregulation of
Noxa. Because E2F1 plays a critical role in controlling S-phase
entry [38,39], these findings indicate that Noxa could mediate
crosstalk between ERa and E2F1/RB, as regulators of E2-induced
cell cycle progression.
Our experiments have, for the first time, revealed a
requirement for Noxa expression during cell cycle progression
in MCF7 breast cancer cells. Loss of Noxa increases the size of
the G1/G0-phase cell population and decreases that of the S-
phase population, suggesting that Noxa expression is required
for S-phase entry in unstressed cells. To strengthen the
significance of these findings, we have eliminated the likelihood
of either mutations occurring within the NOXA gene, or
alternatively spliced NOXA gene products [40] contributing to
the proproliferative functions of Noxa reported here (data not
shown). Our results showing that Noxa expression is required
for S-phase entry in breast cancer cells are further supported by
data from another study which showed that Noxa expression is
induced during the S-phase in actively dividing B cells [41].
Furthermore, enhanced Noxa expression was associated with
p r o s t a t ec a n c e rp r o g r e s s i o ni nar e c e n tr e p o r t[ 4 2 ] ,a n dh i g h
expression of Noxa has also been observed in chronic
lymphocytic leukemia (CLL) cells [43], suggesting that Noxa
likely plays a role in highly proliferating cells of various tissue
types. While additional studies are needed to elucidate the
mechanisms by which Noxa promotes E2-induced cell cycle
progression, it is reasonable to speculate the involvement of
phosphorylation of Noxa at serine 13, since it has been shown
that glucose-dependent phosphorylation of Noxa at serine 13
promotes cell growth via preferential channeling of glucose to
the pentose phosphate pathway (PPP) [17,18]. An intriguing
question is whether a link between estrogen signaling and
Figure 3. E2F1 mediates ERa-binding to the NOXA promoter in the presence of E2. (A) Schematic representation of the NOXA promoter.
Horizontal arrows indicate the primers used for PCR in site-specific ChIP assays. Note that the figure is not drawn to scale. BS: binding site. TSS:
transcription start site. ERE: estrogen response element. KB: distance in kilobases from the TSS. BP: distance in base pairs from the TSS. (B) ChIP assays
were performed on MCF7 cell lysates to detect ERa binding to the NOXA promoter. Anti-ERa antibody or normal rabbit IgG (R IgG; control antibody)
were used to immunoprecipitate ChIP DNA, and ChIP PCR was performed using primers that amplify a putative ERE site at 23.7 kb (lanes 1–3), a non-
specific (NS) negative control site where no binding is expected to occur (lanes 4–6), and the proximal region of the NOXA promoter (lanes 7–9). PCR
products were resolved on agarose gels. (C) Co-immunoprecipitation (co-IP) of protein complexes containing ERa and E2F1. Left panel: normal rabbit
IgG (R IgG; antibody control) or anti-E2F1 antibody was used for immunoprecipitation (IP) and anti-E2F1 and anti-ERa antibodies were used for
immunoblotting (IB). Right panel: R IgG or anti-ERa antibody was used for IP and anti-ERa and anti-EF21 antibodies were used for IB. (D) MCF7 cells
were transfected with non-silencing control (NS) or ERa siRNA for 24 hr, followed by treatment with E2 (10 nM) or vehicle (veh) for 4 hr. The
recruitment of ERa, E2F1, and RB to the proximal region of the NOXA promoter was analyzed by ChIP assays, as in B. (E) Left panel: MCF7 cells were
transfected with non-silencing control (NS) siRNA or E2F1 siRNA for 48 hr, and E2F1 protein levels were monitored by western blotting. Right panel:
MCF7 cells were transfected with E2F1 siRNA for 24 hr and then treated with vehicle (veh) or E2 (10 nM) for 4 hr. Recruitment of ERa to the proximal
region of the NOXA promoter was analyzed by ChIP assays, as in B. (F) MCF7 cells were transfected with non-silencing control (NS) siRNA or E2F1
siRNA for 24 hr and then treated with vehicle (veh) or E2 (10 nM) for 8 hr. Noxa mRNA expression was assayed by qPCR. Graphical data points in F are
means 6 S.D. of three independent experiments (** P,0.01).
doi:10.1371/journal.pone.0029466.g003
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that is conducive to cellular proliferation.
Notably, E2-dependent upregulation of Noxa on its own did not
induce apoptosis in our cell culture model under normal,
unstressed conditions. These results are consistent with earlier
observations that the proapoptotic functions of Noxa are highly
restricted and dependent upon cell type and the context of cellular
stimuli. For example, when wild type mouse embryonic fibroblasts
(MEFs) that had been transduced with E1A, MYC, and H-RAS-
G12V oncogenes were subjected to RNA interference to
downregulate endogenous Noxa, they were protected from p53-
dependent apoptosis, supporting a proapoptotic role for Noxa
under these conditions [44]. On the other hand, hematopoietic
cells from NOXA knockout mice were normally sensitive to
apoptosis induction, suggesting that Noxa was dispensable for
apoptosis in this context [45]. Collectively, these lines of evidence
indicate that Noxa’s pro-apoptotic function is highly regulated and
cell-type specific. Since cell cycle regulation and apoptosis are
closely linked cellular processes, future studies should focus on
identifying the cellular signals that differentially activate the
proproliferative and proapoptotic functions of Noxa.
To conclude, in addition to the already well-documented
proapoptotic function of Noxa, we herein identify a novel role for
Noxa as a positive regulator of cell cycle progression in ER-
positive breast cancer cells. Our studies suggest that these dual
functions of Noxa could have important clinical implications,
especially in ER-positive breast cancer patients and in cases where
chemotherapeutic and hormonal-therapy drugs, which modulate
Noxa expression, are administered. Presumably, in coordination
with other proteins, Noxa could participate in balancing cell
survival and cell death in a stimuli- and cell-context-dependent
manner. Our data suggest that a more detailed understanding of
Noxa’s many roles as a regulator of diverse cellular functions is
required in order to ascertain how Noxa might play a differential
role in normal versus tumorigenic tissues.
Materials and Methods
Cell lines and culture
The human breast cancer cell line MCF7 from ATCC
(Manassas, VA) was maintained in Dulbecco’s Modified Eagle’s
Medium (DMEM) supplemented with 10% fetal bovine serum
(FBS) (Invitrogen) at 37uC, under a humidified atmosphere of 5%
carbon dioxide. Prior to 17b-estradiol (E2) treatment, cells were
cultured in DMEM containing 10% dextran-charcoal-treated FBS
for 3 days.
Figure 4. Noxa knock-down arrests cells in G1/G0 phase and delays E2-induced S-phase entry. (A&B ) MCF7 cells were transfected with
50 nM of non-silencing control (NS) siRNA or Noxa (S1, S2, and S3) siRNA for 24 hr, after which Noxa mRNA expression was analyzed by qPCR (A), and
Noxa protein expression was analyzed by western blotting (B). S1, S2 and S3 are three different siRNA sequences that target different regions of Noxa
mRNA. (C) MCF7 cells were transfected with non-silencing control (NS) siRNA or Noxa siRNA (a pool of S1, S2, and S3) for 0, 1, or 2 days, as indicated.
The number of viable cells was determined using the ‘‘Cell Titer-Glo Assay’’ kit. (D) MCF7 cells were transfected with 50 nM of non-silencing control
(NS) siRNA or Noxa siRNA (a pool of S1, S2, and S3) for 48 hr. Cell cycle distribution was analyzed by flow cytometry using the PI-staining method. (E)
MCF7 cells were transfected with non-silencing control siRNA (NS) or Noxa siRNA (a pool of S1, S2, and S3) for 32 hr, followed by E2 (10 nM) or vehicle
(veh) treatment for 16 hr. The S-phase population was analyzed by flow cytometry using the PI-staining method. (F) Dose titration and timecourse
experiments were performed to determine the effect of E2-induced Noxa expression on apoptosis, using doxorubicin treatment as a positive control.
MCF7 cells were treated with vehicle (Veh), 1.7 mM doxorubicin (Doxo), or increasing concentrations of E2 (10 nM, 50 nM, and 100 nM) for 16 hr or
48 hr, as indicated. Cleaved and uncleaved poly-ADP-ribose polymerase (PARP) protein expression was analyzed by western blotting. Graphical data
points in A, C, D, and E are means 6 S.D. of three independent experiments (*** P,0.001).
doi:10.1371/journal.pone.0029466.g004
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siRNA at a final concentration of 50 nM was transfected into
cells using Lipofectamine 2000 (Invitrogen). At various time points
after transfection and treatment, cells were harvested and
processed for RNA and protein analysis. The following siRNA
were purchased from Dharmacon: Non-silencing control (NS)
siRNA (catalogue #D-001206-13-20), ERa siRNA (catalogue
#M-003401-04-10), and p53 siRNA (catalogue #M-003329-01-
0050). The following siRNA were purchased from Ambion:
c-Myc siRNA (catalogue #AM4250), E2F1 siRNA (catalogue
#AM16708), and Noxa siRNA (catalogue #16708A). For Noxa
siRNA, 3 different siRNA sequences were used alone or in
combination, as indicated in the figure legends: S1 (ID #5926); S2
(ID #144355) and S3 (ID #144356).
Quantitative real-time polymerase chain reaction (qPCR)
qPCR was performed as described previously [46,47]. Briefly,
total RNA was isolated using the Absolutely RNA Miniprep Kit
(Stratagene). For analyzing the mRNA expression of different
genes, 500 ng of total RNA was reverse transcribed in a 20 mL
reaction using the iScript cDNA Synthesis Kit (Bio-Rad). qPCR
was carried out in a Prism 7300 Sequence Detection System
(Applied Biosystems) using SYBR Green Supermix (Bio-Rad). The
relative mRNA levels were calculated using the DDCt method
using endogenous b-actin mRNA as an internal control. The
following primer sets were used for qPCR:
Actin forward: 59-ATG GGT CAG AAG GAT TCC TAT-39
Actin reverse: 59-AAG GTC TCA AAC ATG ATC TGG G-39
NOXA forward: 59-GCA GAG CTG GAA GTC GAG TGT-
39
NOXA reverse: 59-CTC TTT TGA AGG AGT CCC CTC
AT-39
pS2 forward: 59-CGT GAA AGA CAG AAT TGT GGT
TTT-39
pS2 reverse: 59-CGT CGA AAC AGC AGC CCT TA-39
NCL forward: 59-TGC TGC GGA GAT CAG ATT AGT C-
39
NCL reverse: 59-CAT CGA TCT CTG TTC CCT GCT T-39
Cell cycle analysis
MCF7 cells were harvested after siRNA transfection and E2
treatment. Cell cycle distribution was assayed by staining total
cellular DNA with propidium iodide (PI). Flow cytometry was
performed on a FACScan cytometer (Pharmingen), and the results
were analyzed using ModFit software.
Cell viability assay
The Cell Titer-Glo Assay kit (Promega) was used to assay the
number of viable cells by measuring total ATP levels, according to
the manufacturer’s instructions.
Chromatin immunoprecipitation (ChIP) assay
ChIP was performed as described previously [46,47]. Briefly,
MCF7 cells were washed once with phosphate buffered saline
(PBS) and then crosslinked with 1.5% formaldehyde at 37uC for
10 minutes. After washing with ice cold PBS twice, the cells were
collected in lysis buffer (0.5% SDS, 5.6 mM EDTA, 33 mM Tris-
HCl, pH 8.1, 0.5% Triton X-100, 84 mM NaCl) and lysed for
30 minutes on ice. Cell lysates were sonicated using a Sonicator
3000 (Misonix, NY) and then diluted 5-fold with dilution buffer
(0.01% SDS, 1.2 mM EDTA, 16.7 mM Tris-HCl, pH 8.1, 1.1%
Triton X-100, 167 mM NaCl). Diluted cell lysates were pre-
cleared with salmon sperm DNA/Protein A agarose (Millipore) for
2 hours at 4uC. Five micrograms of specific antibody or normal
IgG were used to immunoprecipitate protein-DNA complexes
from pre-cleared supernatants containing 200 mg of protein.
Immunoprecipitated DNA was amplified by PCR using Accu-
Prime TaqDNA Polymerase (Invitrogen), resolved by agarose gel
electrophoresis, and visualized with ethidium bromide staining. To
analyze protein binding to the NOXA promoter, the following
primer set was used: forward, 59-TAC GTC ACC AGG GAA
GTT CTC A-39; reverse, 59-GGA ACC TCA GCC TCC AAC
TG-39. A control (nonspecific, NS) site within the NOXA promoter
(at 22 kB) was analyzed using the following primer set: forward,
59-AGG GTG CGT ATT TGA ACG AC-39; reverse, 59-GGC
TGA TGT TGG CTG TTT TT-39. To analyze a potential ERE
site (at 23.7 kB), the following primer set was used: forward, 59-
GCT GGA GTG CAA TGG TGT AA-39; reverse, 59-CAG TGT
GGC TCA CGC TTG TA-39.
Co-immunoprecipitation (co-IP) assay
Co-IP assays were performed as described previously [47].
Briefly, MCF7 cells were washed in PBS and harvested in NENT
buffer containing a protease inhibitor cocktail (Roche Diagnostics).
After lysis for 30 min at 4uC, the whole cell lysate was cleared by
centrifugation for 10 min at 14,000 rpm at 4uC. Two mg of lysate
was then precleared with protein G/agarose beads (Invitrogen)
and subsequently incubated with 6 mg of normal IgG or specific
antibody overnight at 4uC. Antibody-bound protein complexes
were immunoprecipitated with protein G/agarose, washed 3 times
with NENT buffer, boiled in SDS sample buffer, and resolved by
SDS-PAGE, followed by western blotting analysis. Protein bands
were visualized using the ECL method (Pierce).
Antibodies
Normal mouse IgG (sc-2025), normal rabbit IgG (sc-2027), and
antibodies against Noxa (sc-26917), c-Myc (sc-40), RB (sc-50),
E2F1 (sc-193), ERa (sc-543, sc-8005), and p53 (sc-126) were
purchased from Santa Cruz Biotechnology. The b-actin antibody
(A2066) was purchased from Sigma. The PARP antibody (#9542)
was obtained from Cell Signaling. Horseradish peroxidase-
conjugated secondary antibodies were obtained from Bio-Rad.
Statistical analysis
Graphical data values are represented as means of triplicate
experiments 6 standard deviations. Unpaired Student’s t-tests
were performed to analyze the differences between control and
experimental groups. A p-value less than 0.05 was considered to be
statistically significant.
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